Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 37Neoplasms 30Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Rectal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Glioma 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Skin Neoplasms 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × trametinib × Clear all
NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
117 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡